Ashley McEvoy serves as President and Chief Executive Officer of Insulet Corporation, a pioneering medical technology company renowned for its Omnipod insulin management system. She assumed the CEO role in February 2022, following her appointment as Chief Operating Officer in October 2020. With nearly three decades of leadership experience in the healthcare industry, McEvoy brings a proven track record of driving innovation, commercial growth, and global expansion. Prior to Insulet, she spent over 25 years at Johnson & Johnson, where she held senior executive positions, culminating as Executive Vice President and Worldwide Chair of the DePuy Synthes franchise, the company's largest orthopaedics business. Under McEvoy's stewardship, Insulet has accelerated its mission to improve lives for people with diabetes through tubeless, wearable insulin delivery technology. She has overseen significant milestones, including the launch of next-generation Omnipod products like the Omnipod 5 automated insulin delivery system, strategic partnerships with digital health platforms, and robust revenue growth exceeding 20% annually. Her leadership has positioned Insulet as a leader in the diabetes care market, expanding access to user-friendly therapies and advancing personalized medicine. McEvoy's achievements extend beyond operations; she is a champion for diversity and inclusion in STEM fields and serves on the boards of several prominent organizations, including the Advanced Medical Technology Association (AdvaMed). Her strategic vision emphasizes patient-centric innovation, operational excellence, and sustainable growth, solidifying Insulet's role at the forefront of diabetes management solutions.